News

The FDA has approved belzutifan to treat patients with advanced renal cell carcinoma (RCC) who have already undergone PD-1 or PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Compared with CAR T-cell therapy, autologous hematopoietic cell transplantation lowered relapse and progression rates in relapsed large B-cell lymphoma.

Eflornithine (Iwilfin) received FDA approval to reduce the risk for relapse in pediatric and adult patients with high-risk neuroblastoma, making it the first therapy to reduce risk for relapse in children with the disease.

The FDA has granted priority review to mirvetuximab soravtansine for folate receptor α (FRα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The rate of minimal residual disease negativity at 21 months was 77% among patients who received isatuximab-irfc, carfilzomib, lenalidomide, and dexamethasone.

Kristin Daly, MSN, ANP-BC, AOCNP, explains how providers approach staging and treatment decision-making in head and neck cancer.

Leah Shaw, MSN, APRN, AGPCNP-BC; and Jessica Deinert, MSN, APRN, FNP-BC, share their clinical pearls in managing treatment-related adverse events in prostate cancer care.

A new targeted therapy showed promising response rates in pediatric and adult patients with relapsed/refractory KMT2A rearranged acute leukemia.

A priority review of nivolumab plus cisplatin-based chemotherapy as a frontline treatment option for adult patients with unresectable or metastatic urothelial carcinoma is underway.

Adding navitoclax to ruxolitinib improved spleen volume reduction, but not total symptom score in patients with myelofibrosis.

The use of pirtobrutinib following covalent Bruton tyrosine kinase inhibitor therapy may be an important sequencing approach in chronic lymphocytic leukemia/small lymphocytic lymphoma, according to recent research.

Remote patient monitoring following CAR T-cell therapy may reduce costs while allowing nurses to maintain a close eye on patient parameters, although more research is needed to refine the process of alerting virtual nurses of potential issues.

The 5-year event-free survival rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab, compared with 72.3% in those who received placebo/chemotherapy plus placebo.

Data from the phase 3 EMERALD trial showed that elacestrant’s benefit was consistent across various subgroups.

Findings from the ADAPTcycle trial suggest that endocrine therapy plus ovarian suppression can generate high response rates in patients with hormone receptor-positive early breast cancer, regardless of age.

Trastuzumab deruxtecan showed the longest time to next treatment in patients with HER2-positive breast cancer or with stable HER2-low disease among the primary and metastatic setting.

The median overall survival with pembrolizumab/olaparib was 25.1 months vs 23.4 months with pembrolizumab plus chemotherapy.

Different subsets of patients with estrogen receptor-positive breast cancer achieved better pathologic complete response rates with neoadjuvant pembrolizumab/chemotherapy vs placebo/chemotherapy.

The primary analysis of the phase 3 HER2CLIMB-02 demonstrates that tucatinib slowed disease progression in patients with HER2-positive metastatic breast cancer, including those with brain metastases.

A consistent progression-free and overall survival benefit was reported among patients with hormone receptor-positive, HER2-negative advanced breast cancer, regardless of age.

Patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer reported positive outcomes following treatment with capivasertib plus fulvestrant.

A smoking-duration cutoff may be a better measure for determining lung cancer screening eligibility compared with smoking pack-years.

Oncology nurses should be ready to offer informative guidance to patients and their families concerning the ongoing FDA inquiry and its potential impact.

Frontline treatment with enfortumab vedotin/pembrolizumab is associated with the highest healthcare costs for patients with locally advanced or metastatic urothelial carcinoma.

The FDA has granted enfortumab vedotin plus pembrolizumab priority review status for patients with locally advanced or metastatic urothelial cancer following data from the phase 3 EV-302/KEYNOTE-A39 trial.

Stephanie L. Graff, MD, FACP; Christine McGinn, MSN, APRN, ACNP-BC; and Jeanine Showalter, MSN, APRN, FNP-BC, AOCNP, share how they approach treatment decision-making following a brain metastasis.

Frontline cadonilimab (AK104) and platinum-based chemotherapy improved progression-free survival in patients with recurrent or metastatic cervical cancer.